West Nile virus drug discovery

Area of Science:

• Virology
• Drug Discovery
• Immunotherapy

Background:

• The 1999 West Nile virus (WNV) outbreak highlighted the urgent need for effective antiviral treatments.
• WNV has since spread globally, necessitating intensified research into therapeutic strategies.

Purpose of the Study:

• To review the current landscape of West Nile virus drug discovery efforts.
• To assess the progress and challenges in developing WNV antiviral therapies.

Main Methods:

• Review of various WNV inhibitor screening approaches: viral infection-based, enzyme-based, structure-based virtual screening, rational design, and antibody-based therapy.
• Analysis of small molecule inhibitors, including challenges in optimization.
• Evaluation of cross-inhibition by antivirals developed for related flaviviruses (e.g., dengue, hepatitis C).

Main Results:

• Multiple screening strategies have identified inhibitors targeting WNV replication.
• Small molecule inhibitors have generally exhibited poor drug-like properties, hindering preclinical development.
• Antivirals for dengue and hepatitis C viruses show cross-inhibitory potential against WNV.
• Therapeutic antibodies have demonstrated significant efficacy in preclinical models, with one advancing to clinical trials.

Conclusions:

• Despite challenges with small molecule inhibitors, repurposed antivirals and antibody-based therapies represent promising avenues for WNV treatment.
• Accumulated knowledge over 15 years provides a stronger foundation for flavivirus antiviral development, including WNV.